



17α-OH Progesterone Scientific Unit (17-OHP-SI) Test System Product Code: 9975-300

1.0 INTRODUCTION

Intended Use: The Quantitative Determination of 17α-OH Progesterone Concentration in Human Serum or Plasma by a Microplate Enzyme Immunoassay, Chemiluminescence.

2.0 SUMMARY AND EXPLANATION OF THE TEST

Plasma/Serum concentrations of 17α-hydroxyprogesterone (17-OHP) are valuable in the initial diagnosis of congenital adrenal hyperplasia (CAH).^{1,2} This common inborn error of metabolism is usually characterized by deficiency in the C21-hydroxylase enzyme system, and necessitates steroid replacement therapy. Adequacy of treatment has been monitored by determining circulating 17-OHP concentrations.^{3,4}

The incidence is roughly estimated to be 1 in 15,000 newborns and can reach as high as 1 in 1480 in native Alaskans. Early diagnosis is valuable to detect CAH in newborns afflicted with the disease, not clinically recognizable, but which will lead to life threatening adrenal crisis in the neonatal period, and to determine the cause of infants with ambiguous genitalia. Delayed diagnosis may also lead to further virilization in female children, acceleration of skeletal maturation and premature development of secondary sex characteristics in male children. Prompt treatment can save the life of infants and allow afflicted children to attain normal growth.

17-OHP is a steroid produced in the adrenal cortex and the gonads. It is the immediate precursor to 11-desoxycortisol (CpS) which is converted to cortisol. Because CpS is produced by 21-hydroxylation of 17-OHP, measurement of 17-OHP is an indirect indicator of 21-hydroxylase activity. CAH occurs where there is a deficiency of this enzyme. The result is a decrease in the conversion of 17-OHP to CpS which blocks the normal synthesis of cortisol. Due to the feedback mechanism, a decrease in cortisol causes an increase in ACTH secretion resulting in adrenal hyperplasia. As 17-OHP is not being converted, increased concentrations of this steroid will be found.

17-OHP concentration increases during pregnancy in the maternal and fetal blood. After birth, values decline rapidly to reach normal adult values in 2 to 7 days. Thus it is advisable not to collect samples before the 3rd day of life. Premature and sick term infants exhibit 2 to 3 fold 17P values with no CAH disorder. It is suggested that a different cut off be adapted to pre-term and sick infants.

In this method, a sample containing 17-OHP is dispensed into a microplate well. An enzyme labeled 17-OHP derivative and biotinylated anti-17αOH-Progesterone are then added. After a suitable incubation, the antibody fraction is separated from unbound enzyme reagent.


The employment of several serum references of known 17-OHP

concentration permits construction of a graph of activity and concentration. From comparison to the dose response curve, an unknown specimen's activity can be correlated with 17α-OH Progesterone concentration.

3.0 PRINCIPLE

Competitive Enzyme Immunoassay (TYPE 7):

The essential reagents required for an enzyme immunoassay include antibody, tracer-antigen conjugate and native antigen. Upon mixing biotinylated antibody, enzyme-antigen conjugate and a serum containing the native antigen, a competition reaction results between the native antigen and the enzyme-antigen conjugate for a limited number of antibody binding sites. The interaction is illustrated by the following equation:



Ab_{Bn} = Biotinylated Antibody (Constant Quantity)

Ag = Native Antigen (Variable Quantity)

Enz-Ag = Enzyme-antigen Conjugate (Constant Quantity)

AgAb_{Bn} = Antigen-Antibody Complex

Enz-AgAb_{Bn} = Enzyme-antigen Conjugate -Antibody Complex

k_a = Rate Constant of Association

k_{-a} = Rate Constant of Disassociation

K = k_a / k_{-a} = Equilibrium Constant

A simultaneous reaction between the biotin attached to the antibody and the streptavidin immobilized on the microwell occurs. This effects the separation of the antibody bound fraction after decantation or aspiration.

AgAb_{Bn} + Enz-AgAb_{Bn} + Streptavidin_{CW} ⇌ immobilized complex

Streptavidin_{CW} = Streptavidin immobilized on well

Immobilized complex = sandwich complex bound to the solid surface

The tracer activity in the antibody bound fraction is inversely proportional to the native antigen concentration. By utilizing several different serum references of known antigen concentration, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained.

4.0 REAGENTS

A. 17-OHP-SI Calibrators – 2ml – Icon A and 1ml/vial - Icons B-G

Six (6) vials of serum reference for 17-OHP at concentrations of 0 (A), 0.1 (B), 0.5 (C), 1.0 (D), 2.5 (E), 10 (F) and 20 (G) ng/ml. Store at 2-8°C. A preservative has been added. The calibrators can be expressed in molar concentrations (nM/L) by multiplying by 3.03.

For example: 1ng/ml x 3.03 = 3.03 nM/L

B. 17-OHP-SI Tracer Reagent – 6ml/vial – Icon ☒

One (1) ready to use vial of 17-OHP (Analog)-horseradish peroxidase (HRP) conjugate in a protein stabilizing matrix with buffer, red dye, preservative and binding protein inhibitors. Store at 2-8°C.

C. 17-OHP-SI Biotin Reagent – 6ml/vial – Icon ▽

One (1) vial of reagent contains anti-17-OHP biotinylated purified rabbit IgG conjugate in buffer, blue dye and preservative. Store at 2-8°C.

D. Light Reagent Wells – 96 wells – Icon ↓

One 96-well white microplate coated with streptavidin and packaged in an aluminum bag with a drying agent. Store at 2-8°C.

E. Wash Solution Concentrate – 20ml/vial – Icon ♣

One (1) vial contains a surfactant in buffered saline. A preservative has been added. Store at 2-8°C.

F. Signal Reagent A – 7ml/vial – Icon C^A

One (1) vial contains luminol in a buffer. Store at 2-8°C.

G. Signal Reagent B – 7ml/vial – Icon C^B

One (1) vial contains hydrogen peroxide (H₂O₂) in buffer. Store at 2-8°C.

H. Product Instructions

Note 1: Do not use reagents beyond the kit expiration date.

Note 2: Avoid extended exposure to heat and light. **Opened reagents are stable for sixty (60) days when stored at 2-8°C. Kit and component stability are identified on label.**

Note 3: Above reagents are for a single 96-well microplate.

4.1 Required But Not Provided:

1. Pipette capable of delivering 0.025ml (25μl), 0.050ml (50μl) and 0.100 ml (0.100 μl) 1.0ml (1000 μl) with a precision of better than 1.5%.
2. Dispenser(s) for repetitive deliveries of 0.050ml (50μl) 0.100ml (100μl) and 0.350ml (350μl) volumes with a precision of better than 1.5%.
3. Microplate washer or a squeeze bottle (optional).
4. Microplate Luminometer.
5. Test tubes for signal A and B
6. Absorbent Paper for blotting the microplate wells.
7. Plastic wrap or microplate covers for incubation steps.
8. Vacuum aspirator (optional) for wash steps.
9. Timer.
10. Quality control materials.

5.0 PRECAUTIONS

**For In Vitro Diagnostic Use
Not for Internal or External Use in Humans or Animals**

All products that contain human serum have been found to be non-reactive for Hepatitis B Surface Antigen, HIV 1&2 and HCV Antibodies by FDA required tests. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, "Biosafety in Microbiological and Biomedical Laboratories," 2nd Edition, 1988, HHS Publication No. (CDC) 88-8395.

Safe Disposal of kit components must be according to local regulatory and statutory requirement.

6.0 SPECIMEN COLLECTION AND PREPARATION

The specimens shall be blood serum or heparinized plasma in type and taken with the usual precautions in the collection of venipuncture samples. For accurate comparison to establish normal values, a fasting morning serum sample should be obtained. The blood should be collected in a redtop (with or without gel additives) venipuncture tube or for plasma use evacuated tube(s) containing heparin. Allow the blood to clot for serum samples. Centrifuge the specimen to separate the serum or plasma from the cells.

In patients receiving therapy with high biotin doses (i.e. >5mg/day), no sample should be taken until at least 8 hours after the last biotin administration, preferably overnight to ensure fasting sample.

Samples may be refrigerated at 2-8°C for a maximum period of five (5) days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of -20°C for up to 30 days. Avoid use of contaminated devices. Avoid repetitive freezing and thawing. When assayed in duplicate, 0.050ml (50μl) of the specimen is required.

7.0 QUALITY CONTROL

Each laboratory should assay controls at levels in the low, normal and high range for monitoring assay performance. These controls should be treated as unknowns and values determined in every test procedure performed. Quality control charts should be maintained to follow the performance of the supplied reagents. Pertinent statistical methods should be employed to ascertain trends. The individual laboratory should set acceptable assay performance limits. In addition, maximum absorbance should be consistent with past experience. Significant deviation from established performance can indicate unnoticed change in experimental conditions or degradation of kit reagents. Fresh reagents should be used to determine the reason for the variations.

8.0 REAGENT PREPARATION

1. Wash Buffer

Dilute contents of wash solution concentrate to 1000ml with distilled or deionized water in a suitable storage container.

Diluted buffer can be stored at 2-30°C for up to 60 days.

2. Working Signal Reagent Solution - Store at 2 - 8°C.

Determine the amount of reagent needed and prepare by mixing equal portions of Signal Reagent A and Signal Reagent B in a clean container. For example, add 1 ml of A and 1ml of B per two (2) eight well strips (A slight excess of solution is made). **Discard the unused portion if not used within 36 hours after mixing.** If complete utilization of the reagents is anticipated, within the above time constraint, pour the contents of Signal Reagent B into Signal Reagent A and label accordingly.

Note: Do not use reagents that are contaminated or have bacteria growth.

9.0 TEST PROCEDURE

Before proceeding with the assay, bring all reagents, reference calibrators and controls to room temperature (20 - 27°C).

****Test Procedure should be performed by a skilled individual or trained professional****

1. Format the microplates' wells for each serum reference, control and patient specimen to be assayed in duplicate. **Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8°C.**
2. Pipette 0.025ml (25μL) of the appropriate serum reference, control or specimen into the assigned well.
3. Add 0.050ml (50μl) of ready to use 17-OHP-SI Tracer Reagent to all wells.
4. Swirl the microplate gently for 20-30 seconds to mix.
5. Add 0.050ml (50μl) of the 17-OHP-SI Biotin Reagent to all wells.
6. Swirl the microplate gently for 20-30 seconds to mix
7. Cover and incubate for 45 minutes at room temperature.
8. Discard the contents of the microplate by decantation or aspiration. If decanting, blot the plate dry with absorbent paper.
9. Add 0.35ml (350μl) of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat four (4) additional times for a total of five (5) washes. **An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat four (4) additional times.**
10. Add 0.100ml (100μl) of working signal reagent solution to all wells (see Reagent Preparation Section). **Always add reagents in the same order to minimize reaction time differences between wells.**
11. Incubate at room temperature for five (5) minutes in the dark.
12. Read the relative light units (RLUs) in each well with a chemiluminescence microplate reader for 0.5-1.0 seconds. **The results should be read within 30 minutes after adding the working Signal Reagent.**

Note: Dilute the samples suspected of concentrations higher than 20 ng/ml 1:1 and 1:5 with 17αOH-Progesterone '0' ng/ml calibrator or male patient serum pools with a known low value for 17αOH-Progesterone.

10.0 CALCULATION OF RESULTS

A dose response curve is used to ascertain the concentration of 17-OHP in unknown specimens.


1. Record the absorbance obtained from the printout of the microplate reader as outlined in Example 1.
2. Plot the absorbance for each duplicate serum reference versus the corresponding 17-OHP concentration in ng/ml on linear graph paper (do not average the duplicates of the serum references before plotting).
3. Connect the points with a best-fit curve.
4. To determine the concentration of 17-OHP for an unknown, locate the average RLUs of the duplicates for each unknown on the vertical axis of the graph, find the intersecting point on the curve, and read the concentration (in ng/ml) from the horizontal axis of the graph (the duplicates of the unknown may be averaged as indicated). In the following example, the average RLUs (11896) intersects the dose response curve at 2.1 ng/ml 17αOH-Progesterone concentration (See Figure 1).

Note: Computer data reduction software designed for chemiluminescence assay may also be used for the data reduction. **If such software is utilized, the validation of the software should be ascertained.**

EXAMPLE 1

Sample I.D.	Well Number	RLUs (A)	Mean RLU (B)	Value (ng/ml)
Cal A	A1	99223	100000	0.0
	B1	100777		
Cal B	C1	75560	75090	0.1
	D1	74620		
Cal C	E1	36670	36821	0.5
	F1	36972		
Cal D	G1	21447	21717	1.0
	H1	21988		
Cal E	A2	8316	8367	2.5
	B2	8419		
Cal F	C2	1045	1069	10.0
	D2	1094		
Cal F	E2	323	324	20.0
	F2	326		
Pat# 1	A3	11638	11896	2.1
	B3	12154		

* The data presented in Example 1 and Figure 1 is for illustration only and **should not** be used in lieu of a dose response curve prepared with each assay. Do not use for calculating your results. In addition, the RLUs of the calibrators have been normalized to 100,000 RLUs for the A calibrator (greatest light output). This conversion minimizes differences caused by efficiency of the various instruments that can be used to measure light output.



11.0 Q.C. PARAMETERS

In order for the assay results to be considered valid the following criteria should be met:

1. The Dose Response Curve should be within established parameters
2. Four out of six quality control pools should be within the established ranges.

12.0 RISK ANALYSIS

The MSDS and Risk Analysis Form for this product are available on request from Monobind Inc.

12.1 Assay Performance

1. It is important that the time of reaction in each well is held constant to achieve reproducible results.
2. Pipetting of samples should not extend beyond ten (10) minutes to avoid assay drift.
3. Highly lipemic, hemolyzed or grossly contaminated specimen(s) should not be used.
4. If more than one (1) plate is used, it is recommended to repeat the dose response curve.
5. The addition of signal reagent initiates a kinetic reaction, therefore the signal reagent(s) should be added in the same sequence to eliminate any time-deviation during reaction.

6. Failure to remove adhering solution adequately in the aspiration or decantation wash step(s) may result in poor replication and spurious results.
7. Use components from the same lot. No intermixing of reagents from different batches.
8. Accurate and precise pipetting, as well as following the exact time and temperature requirements prescribed are essential. Any deviation from Monobind's IFU may yield inaccurate results.
9. All applicable national standards, regulations and laws, including, but not limited to, good laboratory procedures, must be strictly followed to ensure compliance and proper device usage.
10. It is important to calibrate all the equipment e.g. Pipettes, Readers, Washers and/or the automated instruments used with this device, and to perform routine preventative maintenance.
11. Risk Analysis: as required by CE Mark IVD Directive 98/79/EC - for this and other devices, made by Monobind, can be requested via email from Monobind@monobind.com.

12.2 Interpretation

1. **Measurements and interpretation of results must be performed by a skilled individual or trained professional.**
2. Laboratory results alone are only one aspect for determining patient care and should not be the sole basis for therapy, particularly if the results conflict with other determinants.
3. The reagents for AccuLite® CLIA procedure have been formulated to eliminate maximal interference; however, potential interaction between rare serum specimens and test reagents can cause erroneous results. Heterophilic antibodies often cause these interactions and have been known to be problems for all kinds of immunoassays (Boscato LM, Stuart MC. 'Heterophilic antibodies: a problem for all immunoassays' Clin. Chem. 1988;34(27-33). For diagnostic purposes, the results from this assay should be in combination with clinical examination, patient history and all other clinical findings.
4. For valid test results, adequate controls and other parameters must be within the listed ranges and assay requirements.
5. If test kits are altered, such as by mixing parts of different kits, which could produce false test results, or if results are incorrectly interpreted, **Monobind shall have no liability.**
6. If computer controlled data reduction is used to interpret the results of the test, it is imperative that the predicted values for the calibrators fall within 10% of the assigned concentrations.

13.0 EXPECTED RANGES OF VALUES

In agreement with established reference intervals for a "normal" adult population and females during gestation the expected ranges for the 17-OHP-SI AccuLite® CLIA Test System are detailed in Table 1.

TABLE 1
Expected Values for the 17-OHP-SI

	(ng/ml)	(nmol/L)
Prepubertal Child (1-10 yr)	0.2 – 0.8	0.64 – 2.54
Adult man	0.2 – 3.1	0.64 – 9.86
Adult woman		
Follicular phase	0.20-1.30	0.64 – 4.13
Luteal phase	1.00 – 4.51	3.18 – 14.34
Postmenopausal woman	0.2 – 0.9	0.64 – 2.86

TABLE 2
Expected Gestation Values

Gestation Week	1-6	7-14	15-24	25-33	34-40
nmol/L	4-10	3-9	5-14	6-31	8-36
ng/ml	1.32-3.30	1.1-2.8	1.65-4.62	1.98-10.2	2.64-13.20

It is important to keep in mind that establishment of a range of values which can be expected to be found by a given method for a population of "normal" persons is dependent upon a multiplicity of factors: the specificity of the method, the population tested and the precision of the method in the hands of the analyst. For these reasons each laboratory should depend upon the range of expected values established by the manufacturer only until an in-house range can be determined by the analysts using the method with a population indigenous to the area in which the laboratory is located.

14.0 PERFORMANCE CHARACTERISTICS

14.1 Precision

The within and between assay precision of the 17-OHP-SI AccuLite® CLIA Test System were determined by analyses on three different levels of pool control sera. The number, mean values, standard deviation and coefficient of variation for each of these control sera are presented in Table 3 and Table 4.

TABLE 3
Within Assay Precision (Values in ng/ml)

Sample	N	X	σ	C.V.
Low	20	0.94	0.06	8.5%
Normal	20	3.25	0.22	6.7%
High	20	7.38	0.43	5.8%

TABLE 4
Between Assay Precision (Values in ng/ml)

Sample	N	X	σ	C.V.
Low	10	0.88	0.07	8.0%
Normal	10	3.12	0.24	7.7%
High	10	7.55	0.48	6.4%

As measured in ten experiments in duplicate over a ten day period.

14.2 Sensitivity

The 17-OHP-SI AccuLite® CLIA Test System has a sensitivity of 0.03ng/ml. The sensitivity was ascertained by determining the variability of the 0 ng/ml serum calibrator and using the 2σ (95% certainty) statistic to calculate the minimum dose.

14.3 Accuracy

The 17-OHP-SI AccuLite® CLIA Test System was compared with a reference method. Biological specimens from low, normal and high 17-OHP level populations were used (the values ranged from < 0.15 ng/ml – 128 ng/ml). The total number of such specimens was 66. The least square regression equation and the correlation coefficient were computed for this method in comparison with the reference method. The data obtained is displayed in Table 5.

TABLE 5

Method	Mean (x)	Least Square Regression Analysis	Correlation Coefficient
This Method (Y)	3.49	Y = 0.2232 + 1.065(x)	0.957
Reference (X)	3.19		

Only slight amounts of bias between this method and the reference method are indicated by the closeness of the mean values. The least square regression equation and correlation coefficient indicates excellent method agreement.

14.4 Specificity

The % cross reactivity of the 17-OHP-SI antibody to selected substances was evaluated by adding the interfering substance to a serum matrix at various concentrations. The cross-reactivity was calculated by deriving a ratio between dose of interfering substance to dose of 17-OHP needed to displace the same amount of labeled analog.

Substance	Cross Reactivity
17αOH-Progesterone	100.000
Progesterone	0.375
Androstenedione	0.158
Cortisone	0.014
Corticosterone	0.347
Cortisol	0.005
Danazol	0.003
Dihydrotestosterone	0.006
DHEA sulfate	0.002
Estradiol	0.004
Estrone	0.003
Estriol	0.002
Prednisone	0.023
Testosterone	0.015
RF	<0.001

15.0 REFERENCES

1. Strott, C.A., Yoshimi, T., and Lipsett, M.B. "Plasma progesterone and 17α-hydroxyprogesterone in normal men and children with congenital adrenal hyperplasia (CAH)". J. Clin. Invest. 48,930(1969).

2. Youssef, N, David R. "Early diagnosis of congenital adrenal hyperplasia by measurement of 17α-OH Progesterone". Clin. Endocrinol. 4,451 (1975).
3. Lippe B.M, LaFranchi, S.H, Lavin, N. "Serum 17α-OH progesterone, progesterone and testosterone and Estradiol in the diagnosis and management of congenital adrenal Hyperplasia". J. Pediatrics 85,782.(1974).
4. Abraham GE. "The application of natural steroid radioimmunoassay to gynecologic endocrinology". In: Abraham GE, editor. *Radioassay Systems in Clinical Endocrinology*, Basel: Marcel Dekker.; 475-529 (1981).
5. Aufrere MB, Benson H. Progesterone: an overview and recent advances. 65:783-800 (1976).
6. Walker R.F, Read GF., and Fahmy D.R. "Adrenal status assessed by direct radioimmunoassay of Cortisol in whole saliva or parotid fluid". Clin. Chem. 24; 1460 (1978).
7. Bacon G.E, Spencer M.L., and Kelch R.P. "Effect of Cortisol therapy on hormonal relationships in congenital adrenal hyperplasia". Clin. Endocrinol. 6, 115 (1977).
8. David M, Fores M.G., "Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency". J. Pediat. 105:799, 1984.
9. August G.P: Growth and development in the normal infant and child. Ibdid.p 79.
10. BIO-ED slide/seminar educational program, Rochester: Bioeducational Publications (1981).
11. Tietz, *Textbook of clinical chemistry*, 2nd ed. Philadelphia: W.B. Saunders, (1994).

Effective Date: 2019-May-24 Rev. 1 DCO: 1334
MP9975 Product Code: 9975-300

Size	96(A)		192(B)	
	A)	28,1ml set	28,1ml sets	28,1ml sets
Reagent (fill)	B)	1 (6ml)	2 (6ml)	2 (6ml)
	C)	1 (6ml)	2 (6ml)	2 (6ml)
	D)	1 plate	2 plates	2 plates
	E)	1 (20ml)	1 (20ml)	1 (20ml)
	F)	1 (7ml)	2 (7ml)	2 (7ml)
	G)	1 (7ml)	2 (7ml)	2 (7ml)

For Orders and Inquires, please contact

Monobind Inc.
100 North Pointe Drive
Lake Forest, CA 92630 USA

Tel: +1 949.951.2665 Mail: info@monobind.com
Fax: +1 949.951.3539 Fax: www.monobind.com

IVD
EC REP CEpartner4U, Eindhovenlaan 13
 3951 DBMaarn, The Netherlands
 www.cepartner4u.eu

Please visit our website to learn more about our products and services.

Glossary of Symbols
(EN 980/ISO 15223)

IVD In Vitro - Diagnostic Medical Device	Temperature Limitation Storage Condition (2-8°C)	Consult Instructions for Use
REF Catalogue Number	Contains Sufficient Test for Z	LOT Batch Code
Used By (Expiration Day)	Date of Manufacturer	Manufacturer
EC REP Authorized Rep in European Country	CE European Conformity	